论文部分内容阅读
目的筛选肝细胞癌门静脉癌栓相关的血清蛋白标记物。方法收集肝癌无癌栓患者和肝癌门静脉癌栓患者血清各12例,以弱阳离子交换蛋白质芯片为检测介质,利用表面加强激光解吸电离-飞行时间质谱测定出蛋白质谱,BioMarker Wizard软件筛选出差异蛋白峰,选择其中一个蛋白进行分离纯化和富集,利用基质辅助激光解吸飞行时间质谱对其进行鉴定。结果在m/z 1100～30000范围内,检测出的100个蛋白峰中7个差异有统计学意义(P<0.05),m/z为3397的蛋白峰在肝细胞癌伴门静脉癌栓组中上调,而m/z为7546、7896、8682、15 104、15 857和16 457的蛋白峰在肝细胞癌伴门静脉癌栓组中下调;m/z为8682的差异蛋白经鉴定为载脂蛋白A- I,与无癌栓组比较,门静脉癌栓组中该蛋白表达降低。结论筛选出的蛋白分子标记物可能与肝细胞癌门静脉癌栓形成有关,有可能为肝癌和门静脉癌栓早期预测及治疗监测提供参考。
Objective To screen the serum protein markers related to portal vein tumor thrombus in hepatocellular carcinoma. Methods Twelve patients with hepatocellular carcinoma without tumor thrombus and patients with hepatocellular carcinoma and portal vein tumor thrombus were collected in this study. The protein profiles were determined by surface-enhanced laser desorption ionization-time of flight mass spectrometry with weak cation-exchange protein chip as a detection medium. BioMarker Wizard software was used to screen the differential proteins Peak, select one of the proteins for purification and enrichment, and identify them using matrix-assisted laser desorption-time of flight mass spectrometry. Results There were significant differences among the 100 peaks detected in the range of m / z 1100 ~ 30000 (P <0.05), and the protein peak with m / z 3397 was found in hepatocellular carcinoma with portal vein thrombosis And the protein peak with m / z 7546, 7896, 8682, 15 104, 15 857 and 16 457 was down-regulated in hepatocellular carcinoma with portal vein thrombosis group; the differential protein with m / z 8682 was identified as apolipoprotein A-I, compared with no tumor embolus group, the portal vein tumor thrombosis group in the protein expression decreased. Conclusion The selected protein molecular markers may be related to the formation of portal vein thrombosis of hepatocellular carcinoma, which may provide a reference for the early prediction of liver cancer and portal vein tumor thrombus and treatment monitoring.